Skip to content

Effects of oxygen blood level on inflammation

Effects of oxygen status on endotoxemia induced inflammation and Hypoxia Inducible Factor 1-a. A pilot proof of principle study.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-002390-21-NL
Enrollment
30
Registered
2013-08-20
Start date
2013-09-03
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Possible future indications: inflammatory conditions in general, autoimmune diseases

Interventions

Sponsors

Radboud University Nijmegen Medical Centre
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Age>18 and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Use of any medication - Smoking - History, signs or symptoms of cardiovascular disease - History of atrial or ventricular arrhythmia - (Family) history of myocardial infarction or stroke under the age of 65 years - Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block - Hypertension (defined as RR systolic > 160 or RR diastolic > 90 mmHg) - Hypotension (defined as RR systolic 120 µmol/l) - Liver enzyme abnormalities alkaline phosphatase>230 U/L and/or ALT>90 U/L - Medical history of any obvious disease associated with immune deficiency - CRP > 20 mg/L, WBC > 12x109/L, or clinically significant acute illness, including infections, within 4 weeks before endotoxemia day - Participation in a drug trial or donation of blood 3 months prior to the experiment - Pre-existent pulmonary diseases, including asthma - Use of recreational drugs within 21 days prior to experiment day - Visit to altitude >1500m within 4 weeks prior to the experiment - Air travel with flight time over 3 hours within 4 weeks prior to the experiment - History of acute mountain sickness - Recent hospital admission or surgery with general anaesthesia (<3 months) - Claustrophobia - Feelings of discomfort during a 10 minute test wearing the transparent respiratory helmet at the screening visit

Design outcomes

Primary

MeasureTime frame
Main Objective: The primary objective of the study is to determine the effects of hyperoxia and hypoxia compared to normoxia in the human endotoxemia model on kinetics of plasma TNF alpha in healthy volunteers;Secondary Objective: Secondary objectives are to determine the effects of hyperoxia and hypoxia on HIF-1a protein, HIF-1a mRNA and aHIF mRNA expression in circulating leukocytes, the induction of ROS, the effects on phagocytosis, basic hemodynamic and ventilatory parameters;Primary end point(s): The primary objective of the study is to determine the effects of hypoerxia and hypoxia, comapred with normoxia, in human endotoxemia on plasma TNF-a;Timepoint(s) of evaluation of this end point: at -60, 0, 60, 90, 120, 240, 360 and 480 minutes and 24 hours after LPS administration

Secondary

MeasureTime frame
Secondary end point(s): - HIF-1a protein and mRNA and aHIF mRNA in circulating leukocytes - Circulating cytokines (including, but not limited to IL-6, IL-10, and IL1RA) - ROS - Phagocyting capacity of leukocytes - Cytokine responses by leukocytes ex vivo stimulated with various inflammatory stimuli - Core body temperature - Hemodynamic parameters (heart rate, blood pressure) - Respiratory frequency - Arterial blood gas parameters - Leukocyte counts and differentiation - Illness score - Adenosine metabolism - Cognitive function tests ;Timepoint(s) of evaluation of this end point: at -60, 0, 60, 90, 120, 240, 360 and 480 minutes and 24 hours after LPS administration

Countries

Netherlands

Contacts

Public ContactDorien Kiers

Radboud University Nijmegen Medical Centre

h.kiers@ic.umcn.nl

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026